Abstract
Reactivation of cytomegalovirus (CMV) or Epstein-Barr virus (EBV) is common after hematopoietic stem cell transplantation (HSCT). Previous researches have demonstrated that either CMV or EBV reactivation is associated with poor outcomes of HSCT. However, few studies investigate the impact of CMV and EBV co-reactivation after HSCT. In this study, we described the clinical characteristics of HSCT recipients with CMV and EBV co-reactivation (defined as CMV and EBV viremia occur at the same period of time). We conducted a longitudinal study of 247 patients who underwent HSCT in our center. A total of 24 (9.7%) patients had CMV and EBV co-reactivation. These patients showed higher incidence of viral pneumonitis (P=0.005). Patients with CMV and EBV co-reactivation had significant lower 1-year overall survival (OS) (P=0.004) and lower 1-year leukemia free survival (LFS) (P=0.016). Our further analysis suggested that duration of CMV (P=0.014), EBV (P<0.001), and CD4+CD25+ T cell counts at day 30 post-transplantation (P=0.05) are independent risk factors of virus co-reactivation. In conclusion, patients who developed co-reactivation of CMV and EBV had poor prognosis in terms of lower 1-year OS and LFS, and the CMV and EBV co-reactivation was associated with prolonged CMV or EBV duration and poor CD4+CD25+ T cell reconstitution at day 30 post-transplantation.
Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a primary curative treatment for hematologic malignancies such as Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL). However, the necessary immunosuppression to prevent graft-versus-host disease creates a window of vulnerability to latent herpesviruses, specifically Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV). While individual reactivation of these viruses is known to negatively impact outcomes, the clinical significance of simultaneous co-reactivation—where both viruses are detectable in the blood concurrently—remains less explored.
This study aimed to characterize the clinical impact of CMV and EBV co-reactivation and identify biological markers, particularly immune reconstitution patterns, that predict this occurrence.
Methods
A longitudinal, retrospective analysis was performed on 247 patients who underwent allo-HSCT at Peking University People’s Hospital. Viral DNA levels were monitored twice weekly via real-time quantitative PCR. Co-reactivation was defined as the concurrent presence of CMV and EBV viremia. Additionally, T-lymphocyte subsets (CD3+, CD4+, CD8+, and CD4+CD25+) were analyzed using flow cytometry at 30, 60, and 90 days post-transplant to track how the immune system was rebuilding itself.
Key Results
Out of the 247 patients, 24 (9.7%) experienced CMV and EBV co-reactivation. This group faced significantly worse clinical outcomes compared to those with single or no reactivation.
Survival Outcomes
The impact on survival was stark. The 1-year Overall Survival (OS) for the co-reactivation group was 50%, significantly lower than the 75.6% observed in patients without reactivation ($P=0.004$). Similarly, 1-year Leukemia-Free Survival (LFS) was reduced to 50% in the co-reactivation group compared to 71.8% in the no-reactivation group ($P=0.016$).
Clinical Complications and Risk Factors
Patients with co-reactivation had a higher incidence of viral pneumonitis (20.8% vs. 1.3% in the no-reactivation group, $P=0.005$). Multivariate analysis identified several independent risk factors for co-reactivation:
- Prolonged Viremia: The duration of CMV ($P=0.014$) and EBV ($P<0.001$) viremia were significant predictors, suggesting a bidirectional relationship where one virus facilitates the persistence of the other.
- Immune Reconstitution: Low counts of CD4+CD25+ T cells (often associated with regulatory T cells) at day 30 post-transplantation were significantly associated with a higher risk of co-reactivation ($P=0.05$).
Discussion and Conclusion
The findings suggest that CMV and EBV co-reactivation is a critical prognostic marker after allo-HSCT. The correlation with delayed CD4+CD25+ T cell reconstitution indicates that a failure in specific immune regulatory mechanisms allows these viruses to escape control.
While this study is limited by its retrospective nature and small co-reactivation sample size, it highlights the importance of monitoring viral duration and early immune markers. Future prospective studies are needed to determine if targeted interventions or closer monitoring of CD4+CD25+ T cell subsets can improve survival outcomes for high-risk patients.
Summary updated